Recent Aim new issue Oncimmune Holdings PLC (LON:ONC) has signed up three new US distributors for its early stage lung cancer test.
The agreements will increase the total salesforce across the US selling EarlyCDT-Lung to more than 140 through seven distributors.
All major US markets are now covered said the company, though discussions are also underway with several other distributors.
Geoffrey Hamilton-Fairley, Oncimmune’s chief executive, added: "More than 140,000 EarlyCDT-Lung tests have been sold in the US since we began commercialisation in 2012.
“Our near term strategy in this market is to partner with more distributors and move towards total coverage across the US.”
EarlyCDT-Lung is a simple blood test to aid in the risk assessment and early detection of lung cancer.
Oncimmune floated at 130p a share last week.